Tags

Type your tag names separated by a space and hit enter

Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity.
Thromb Res. 2007; 121(2):145-51.TR

Abstract

BACKGROUND

The complex between activated protein C (APC) and the protein C inhibitor (PCI) is a sensitive indicator of the degree of activation of blood coagulation and higher concentrations have been measured in carriers of the FV Leiden mutation who were in the recovery phase after treatment for venous thromboembolism (VTE).

OBJECTIVES

The main purpose of this study was to correlate the APC-PCI complex concentration to thrombomodulin activity and antigen concentration in the same group of patients. We also add a prospective clinical follow-up of the VTE recurrence after 1 year to investigate if the markers can predict the risk for a new VTE.

PATIENTS/METHODS

Blood samples were collected from 50 patients with the FV Leiden mutation and 132 without any known risk factor for thrombophilia after finished treatment.

RESULTS

The APC-PCI complex, s-TM activity and the quotient (s-TM activity)/(s-TM antigen) were higher in VTE patients with FV Leiden. In total, there were 19 VTE recurrences (10%) after 1 year. The OR for recurrence was 1.9 (95% CI 0.68-5.0) in all VTE patients with elevated APC-PCI complex (above 75th percentile) and 3.6 (95% CI 1.1-12) in VTE patients without any known risk factor for thrombophilia and with elevated s-TM activity.

CONCLUSION

The APC-PCI complex concentration, s-TM activity and the quotient (s-TM activity)/(s-TM antigen) were higher in VTE patients with FV Leiden. The s-TM activity showed higher OR for recurrence of VTE in patients without known thrombophilic risk factor. Both methods could be sensitive markers of increased risk for venous thrombosis.

Authors+Show Affiliations

Department of Clinical Chemistry, Lund University, Malmö University Hospital, SE-205 02 Malmö, Sweden. karin.strandberg@med.lu.seNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17499343

Citation

Strandberg, Karin, et al. "Venous Thromboembolism in Carriers of the Factor V Leiden Mutation and in Patients Without Known Thrombophilic Risk Factor; Prediction of Recurrence and APC-PCI Complex Concentration And/or Soluble Thrombomodulin Antigen and Activity." Thrombosis Research, vol. 121, no. 2, 2007, pp. 145-51.
Strandberg K, Svensson PJ, Ohlin AK. Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity. Thromb Res. 2007;121(2):145-51.
Strandberg, K., Svensson, P. J., & Ohlin, A. K. (2007). Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity. Thrombosis Research, 121(2), 145-51.
Strandberg K, Svensson PJ, Ohlin AK. Venous Thromboembolism in Carriers of the Factor V Leiden Mutation and in Patients Without Known Thrombophilic Risk Factor; Prediction of Recurrence and APC-PCI Complex Concentration And/or Soluble Thrombomodulin Antigen and Activity. Thromb Res. 2007;121(2):145-51. PubMed PMID: 17499343.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity. AU - Strandberg,Karin, AU - Svensson,Peter J, AU - Ohlin,Ann-Kristin, Y1 - 2007/05/11/ PY - 2006/11/19/received PY - 2007/02/19/revised PY - 2007/03/27/accepted PY - 2007/5/15/pubmed PY - 2008/3/14/medline PY - 2007/5/15/entrez SP - 145 EP - 51 JF - Thrombosis research JO - Thromb Res VL - 121 IS - 2 N2 - BACKGROUND: The complex between activated protein C (APC) and the protein C inhibitor (PCI) is a sensitive indicator of the degree of activation of blood coagulation and higher concentrations have been measured in carriers of the FV Leiden mutation who were in the recovery phase after treatment for venous thromboembolism (VTE). OBJECTIVES: The main purpose of this study was to correlate the APC-PCI complex concentration to thrombomodulin activity and antigen concentration in the same group of patients. We also add a prospective clinical follow-up of the VTE recurrence after 1 year to investigate if the markers can predict the risk for a new VTE. PATIENTS/METHODS: Blood samples were collected from 50 patients with the FV Leiden mutation and 132 without any known risk factor for thrombophilia after finished treatment. RESULTS: The APC-PCI complex, s-TM activity and the quotient (s-TM activity)/(s-TM antigen) were higher in VTE patients with FV Leiden. In total, there were 19 VTE recurrences (10%) after 1 year. The OR for recurrence was 1.9 (95% CI 0.68-5.0) in all VTE patients with elevated APC-PCI complex (above 75th percentile) and 3.6 (95% CI 1.1-12) in VTE patients without any known risk factor for thrombophilia and with elevated s-TM activity. CONCLUSION: The APC-PCI complex concentration, s-TM activity and the quotient (s-TM activity)/(s-TM antigen) were higher in VTE patients with FV Leiden. The s-TM activity showed higher OR for recurrence of VTE in patients without known thrombophilic risk factor. Both methods could be sensitive markers of increased risk for venous thrombosis. SN - 0049-3848 UR - https://www.unboundmedicine.com/medline/citation/17499343/Venous_thromboembolism_in_carriers_of_the_Factor_V_Leiden_mutation_and_in_patients_without_known_thrombophilic_risk_factor/or_soluble_thrombomodulin_antigen_and_activity_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0049-3848(07)00122-3 DB - PRIME DP - Unbound Medicine ER -